Resources from the same session
LBA32 - Principal results of the EORTC-1508 trial: A phase II randomised, multicentre study of bevacizumab vs atezolizumab and bevacizumab with acetylsalicylic acid or placebo in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma
Presenter: Susana Banerjee
Session: Proffered Paper session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
721O - Relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel improves progression-free survival in patients with recurrent platinum-resistant ovarian cancer: A 3-arm, randomized, open-label, phase II study
Presenter: Domenica Lorusso
Session: Proffered Paper session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
722O - Randomised phase II trial of olaparib compared to weekly paclitaxel or olaparib plus cediranib in patients with platinum-resistant ovarian cancer (OCTOVA)
Presenter: Shibani Nicum
Session: Proffered Paper session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
LBA33 - Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial
Presenter: Eric Pujade-Lauraine
Session: Proffered Paper session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Q&A and live discussion
Presenter: Rosalind Glasspool
Session: Proffered Paper session - Gynaecological cancers
Resources:
Slides
Webcast
Invited Discussant 722O and LBA33
Presenter: Clare Scott
Session: Proffered Paper session - Gynaecological cancers
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Clare Scott
Session: Proffered Paper session - Gynaecological cancers
Resources:
Slides
Webcast